Elite Journal of Nursing and Health Sciences. Volume 2 issue 1(2024), Pp. 21-31 https://epjournals.com/journals/EJNHS

The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review

*Emmanuel Ifeanyi Obeagu[1] and Getrude Uzoma Obeagu[2]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda.

[2]School of Nursing Science, Kampala International University, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Preeclampsia, a hypertensive disorder of pregnancy, presents unique challenges for women living with HIV. This review explores the potential impact of erythropoietin (EPO) in managing and preventing preeclampsia among HIV-positive women. Drawing from a comprehensive analysis of current literature, the review synthesizes evidence on the physiological roles of EPO, its mechanisms of action, and its potential therapeutic applications in the context of preeclampsia. Special attention is given to the intersection of HIV infection and preeclampsia, examining epidemiological patterns, risk factors, and clinical manifestations specific to this population. The review critically evaluates existing studies investigating EPO as a therapeutic intervention for preeclampsia, addressing both potential benefits and risks. Finally, it identifies gaps in current knowledge and proposes avenues for future research to establish the safety and efficacy of EPO in managing preeclampsia in HIV-positive women. This comprehensive review aims to contribute to the development of tailored management strategies, offering insights into the potential of EPO as a promising therapeutic avenue for improving maternal and neonatal outcomes in this vulnerable population.

Keywords*: Erythropoietin, Preeclampsia, HIV, Women*

Introduction

Preeclampsia, characterized by hypertension and end-organ damage during pregnancy, remains a leading cause of maternal and neonatal morbidity and mortality globally. The management of preeclampsia is particularly complex when considering the added challenges posed by concurrent HIV infection in pregnant women. Women living with HIV encounter a unique set of physiological and immunological factors that may influence the onset and severity of preeclampsia. Erythropoietin (EPO), a glycoprotein hormone traditionally recognized for its pivotal role in

erythropoiesis, has emerged as a potential therapeutic candidate for conditions extending beyond its hematopoietic functions. In recent years, researchers have explored the multifaceted properties of EPO, including its anti-inflammatory, anti-oxidative, and angiogenic effects. This has prompted investigations into the potential impact of EPO on the management and prevention of preeclampsia, especially among women living with HIV.[1-21]

The interaction between HIV infection and preeclampsia is a complex area that demands a nuanced understanding. HIV itself can contribute to systemic inflammation and endothelial dysfunction; processes intricately linked to the pathogenesis of preeclampsia. As such, exploring novel interventions, such as EPO, becomes crucial in addressing the unique healthcare needs of pregnant women navigating both HIV and preeclampsia.[22-36] This review aims to provide a comprehensive overview of the current state of knowledge regarding the impact of EPO on preeclampsia in the specific context of HIV-positive women. By synthesizing existing evidence, we seek to shed light on the potential benefits, challenges, and future directions of integrating EPO into the management strategies for preeclampsia in this vulnerable population. Through this exploration, we aspire to contribute valuable insights that may pave the way for more targeted and effective healthcare approaches for pregnant women at the intersection of HIV and preeclampsia.

Erythropoietin: Mechanisms and Biological Significance

Erythropoietin (EPO) is a glycoprotein hormone that plays a crucial role in the regulation of red blood cell production. EPO is primarily produced in the kidneys, specifically in the peritubular cells of the renal cortex, in response to low oxygen levels in the blood. Hypoxia-inducible factor (HIF) is a key regulator of EPO production. Under hypoxic conditions, HIF stabilizes and translocates to the nucleus, activating the transcription of the EPO gene. The primary role of EPO is to stimulate the production of red blood cells (erythropoiesis) in the bone marrow. EPO acts on hematopoietic stem cells, promoting their differentiation into red blood cells and enhancing the survival and proliferation of erythroid progenitor cells.[37-39]

EPO is a key player in maintaining oxygen homeostasis. Its release is tightly regulated to respond to changes in tissue oxygenation levels. In situations of low oxygen availability, such as at high altitudes or in cases of anemia, EPO secretion increases to boost red blood cell production and enhance oxygen-carrying capacity. Beyond its role in erythropoiesis, EPO has demonstrated anti-apoptotic properties and tissue-protective effects in various organs. Recombinant EPO (rEPO) is widely used in clinical settings to treat anemia associated with chronic kidney disease, chemotherapy, and certain other conditions. Despite its therapeutic benefits, there are concerns about the misuse of EPO, especially in sports, due to its potential to enhance athletic performance by increasing oxygen-carrying capacity.[40-42]

Preeclampsia in HIV-Positive Women

Preeclampsia is a pregnancy-related condition characterized by high blood pressure and damage to organs, typically the liver and kidneys. It usually occurs after 20 weeks of gestation and can have serious implications for both the mother and the baby. While preeclampsia itself is a complex

condition, its occurrence in HIV-positive women adds another layer of complexity. HIV-positive women may face an elevated risk of preeclampsia compared to the general population. The immunological changes associated with HIV infection and the inflammatory response may contribute to this increased risk. Preeclampsia in HIV-positive women can lead to more severe maternal complications. Both conditions involve inflammation and vascular dysfunction, and their coexistence may exacerbate these processes. Preeclampsia may impact the risk of vertical transmission of HIV. The inflammatory environment associated with preeclampsia could potentially influence viral replication and transmission to the fetus.[43-72]

Managing preeclampsia in HIV-positive women requires a multidisciplinary approach. Healthcare providers need to balance the treatment of preeclampsia with the management of HIV, considering potential interactions between antiretroviral medications and those used to control hypertension. Close monitoring of both preeclampsia and HIV is crucial during pregnancy. Regular blood pressure checks, laboratory tests, and viral load monitoring are essential to detect and manage complications early. The use of antiretroviral therapy in HIV-positive pregnant women is standard practice to prevent vertical transmission. The choice of antiretroviral drugs should be carefully considered, taking into account potential interactions with medications used to manage preeclampsia.[73-87]

Erythropoietin as a Therapeutic Intervention

Erythropoietin (EPO) has been explored as a therapeutic intervention in various medical conditions beyond its traditional role in treating anemia associated with chronic kidney disease. EPO is commonly used to stimulate erythropoiesis (red blood cell production). Recombinant EPO (rEPO) is administered in conditions where there is a deficiency of endogenous EPO, such as chronic kidney disease, certain cancers, and chemotherapy-induced anemia. EPO has shown neuroprotective effects in preclinical studies and clinical trials.[88] It has been investigated as a potential treatment for neurological conditions, including stroke, traumatic brain injury, and neurodegenerative disorders. EPO has demonstrated anti-inflammatory properties, which may contribute to its protective effects in various organs. This aspect of EPO is being explored in conditions associated with inflammation and tissue damage.

In addition to its role in treating anemia in chronic kidney disease, EPO has been investigated for its potential renoprotective effects. Studies have explored its impact on renal function and tissue damage. EPO has been considered for its role in promoting wound healing. Its ability to enhance tissue repair and regeneration is of interest in the context of skin wounds and injuries. EPO receptors are expressed in certain cancer cells, and there is ongoing research into the potential use of EPO or EPO analogs in cancer treatment. However, concerns about potential tumor growth promotion have been raised, and more research is needed in this area. Despite its potential benefits, the use of EPO is not without risks. Excessive EPO stimulation can lead to complications such as hypertension, thrombosis, and cardiovascular events. Careful dosing and monitoring are crucial to balance therapeutic benefits with potential risks. The clinical use of EPO varies across different medical specialties. Guidelines and recommendations for its use in specific conditions are typically established based on a careful assessment of the available evidence.[88]

Conclusion

Erythropoietin (EPO) holds therapeutic promise beyond its established role in stimulating erythropoiesis. The multifaceted properties of EPO, including its neuroprotective, cardioprotective, anti-inflammatory, and renoprotective effects, have spurred extensive research into its potential applications in various medical conditions. While EPO has demonstrated efficacy in treating anemia associated with chronic kidney disease and certain cancers, its exploration as a therapeutic intervention extends to neurological disorders, cardiovascular diseases, and tissue damage. The neuroprotective effects of EPO have been particularly noteworthy, with investigations into its potential for mitigating damage in conditions like stroke, traumatic brain injury, and neurodegenerative disorders. Additionally, EPO's impact on cardiovascular health, renal function, and wound healing has sparked interest in its broader therapeutic applications. In the realm of maternal health, EPO's implications for conditions like preeclampsia in HIV-positive women are areas that warrant further investigation. The intersection of EPO, pregnancy-related complications, and underlying health conditions underscores the complexity of therapeutic interventions in specific populations.

References

1. Obeagu EI, Agreen FC. Anaemia among pregnant women: A review of African pregnant teenagers. J Pub Health Nutri. 2023; 6 (1). 2023;138. links/63da799664fc860638054562/Anaemia-among-pregnant-women-A-review-of-African-pregnant-teenagers.pdf.
2. Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in the anaemias of pregnancy: a review. Int J Curr Res Chem Pharm Sci. 2016;3(3):10-8. links/5710fae108ae846f4ef05afb/ERYTHROPOIETIN-IN-THE-ANAEMIAS-OF-PREGNANCY-A-REVIEW.pdf.
3. Obeagu EI, Adepoju OJ, Okafor CJ, Obeagu GU, Ibekwe AM, Okpala PU, Agu CC. Assessment of Haematological Changes in Pregnant Women of Ido, Ondo State, Nigeria. J Res Med Dent Sci. 2021 Apr;9(4):145-8. links/608a6728a6fdccaebdf52d94/Assessment-of-Haematological-Changes-in-Pregnant-Women-of-Ido-Ondo.pdf.
4. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10;6(2):10-3. http://irmhs.com/index.php/irmhs/article/view/111.
5. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.
6. Obeagu EI, Obeagu GU, Chukwueze CM, Ikpenwa JN, Ramos GF. Evaluation of Protein C, Protein S and Fibrinogen of Pregnant Women with Malaria in Owerri Metropolis. Madonna University journal of Medicine and Health Sciences. 2022;2(2):1-9.

7. Obeagu EI, Ikpenwa JN, Chukwueze CM, Obeagu GU. Evaluation of protein C, protein S and fibrinogen of pregnant women in Owerri Metropolis. Madonna University Journal of Medicine and Health Sciences. 2022;2(1):292-8. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/57.
8. Obeagu EI, Obeagu GU, Adepoju OJ. Evaluation of haematological parameters of pregnant women based on age groups in Olorunsogo road area of Ido, Ondo state. J. Bio. Innov11 (3). 2022:936-41.
9. Obeagu EI. An update on utilization of antenatal care among pregnant Women in Nigeria. Int. J. Curr. Res. Chem. Pharm. Sci. 2022;9(9):21-6.DOI: 10.22192/ijcrcps.2022.09.09.003
10. Okoroiwu IL, Obeagu EI, Obeagu GU. Determination of clot retraction in preganant women attending antenatal clinic in federal medical centre Owerri, Nigeria. Madonna University Journal of Medicine and Health Sciences. 2022;2(2):91-7. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/67.
11. Obeagu EI, Hassan AO, Adepoju OJ, Obeagu GU, Okafor CJ. Evaluation of Changes in Haematological Parameters of Pregnant Women Based on Gestational Age at Olorunsogo Road Area of Ido, Ondo State. Nigeria. Journal of Research in Medical and Dental Science. 2021;9(12):462-.links/61b1e32f0c4bfb675178bfa7/Evaluation-of-Changes-in-Haematological-Parameters-of-Pregnant-Women-Based-on-Gestational-Age-at-Olorunsogo-Road-Area-of-Ido-Ondo-State-Nigeria.pdf.
12. Anyiam AF, Obeagu EI, Obi E, Omosigho PO, Irondi EA, Arinze-Anyiam OC, Asiyah MK. ABO blood groups and gestational diabetes among pregnant women attending University of Ilorin Teaching Hospital, Kwara State, Nigeria. International Journal of Research and Reports in Hematology. 2022;5(2):113-121.
13. Obeagu EI. Gestational Thrombocytopaenia. J Gynecol Women's Health. 2023;25(3):556163. links/64b01aa88de7ed28ba95fccb/Gestational-Thrombocytopaenia.pdf.
14. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
15. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-9.
16. Obeagu EI, Okoroiwu IL, Obeagu G. Molecular mechanism and systemic response of erythropoietin: A Review. Int. J. Adv. Res. Biol. Sci. 2015;2(7):58-62.
17. Obeagu EI, Okoroiwu II, Ezimah AC. Evaluation of serum erythropoietin levels in chronic kidney disease patients in Federal Medical centre, Umuahia, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(4):15-21.
18. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-8.
19. Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in the anaemias of pregnancy: a review. Int J Curr Res Chem Pharm Sci. 2016;3(3):10-8.

20. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33.
21. Obeagu EI, Obeagu GU, Nchuma BO, Amazue PO. A Review on erythropoietin receptor (EpoR). Int. J. Adv. Res. Biol. Sci. 2015;2(8):80-4.
22. Obeagu EI, Abdirahman BF, Bunu UO, Obeagu GU. Obsterics characteristics that effect the newborn outcomes. Int. J. Adv. Res. Biol. Sci. 2023;10(3):134-43.DOI: 10.22192/ijarbs.2023.10.03.016
23. Obeagu EI, Ogunnaya FU. PREGNANCYINDUCED HAEMATOLOGICAL CHANGES: A KEY TO MARTERNAL AND CHILD HEALTH. European Journal of Biomedical. 2023;10(8):42-3. links/64c890bddb38b20d6dad2c5c/PREGNANCY-INDUCED-HAEMATOLOGICAL-CHANGES-A-KEY-TO-MARTERNAL-AND-CHILD-HEALTH.pdf.
24. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-9.
25. Okamgba OC, Nwosu DC, Nwobodo EI, Agu GC, Ozims SJ, Obeagu EI, Ibanga IE, Obioma-Elemba IE, Ihekaire DE, Obasi CC, Amah HC. Iron Status of Pregnant and Post-Partum Women with Malaria Parasitaemia in Aba Abia State, Nigeria. Annals of Clinical and Laboratory Research. 2017;5(4):206. links/5ea97df145851592d6a8acf2/Iron-Status-of-Pregnant-and-Post-Partum-Women-with-Malaria-Parasitaemia-in-Aba-Abia-State-Nigeria.pdf.
26. Eze RI, Obeagu EI, Edet FN. Frequency of Rh Antigen C And c among pregnant women in Sub-Urban area in Eastern Nigeria. Madonna Uni J Med Health Sci. 2021;1(1):19-30.
27. Obeagu EI, Ofodile AC, Okwuanaso CB. A review of urinary tract infections in pregnant women: Risks factors. J Pub Health Nutri. 2023; 6 (1). 2023;137:26-35. links/63c3a9116fe15d6a571e8bba/A-review-of-urinary-tract-infections-in-pregnant-women-Risks-factors.pdf.
28. Obeagu EI, Obeagu GU, Musiimenta E. Post partum haemorrhage among pregnant women: Update on risks factors. Int. J. Curr. Res. Med. Sci. 2023;9(2):14-7.DOI: 10.22192/ijcrms.2023.09.02.003
29. Obeagu EI, Obeagu GU, Ogunnaya FU. Deep vein thrombosis in pregnancy: A review of prevalence and risk factors. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(8):14-21.DOI: 10.22192/ijcrcps.2023.10.08.002
30. Jakheng SP, Obeagu EI, Jakheng EW, Uwakwe OS, Eze GC, Obeagu GU, Vidya S, Kumar S. Occurrence of Chlamydial Infection Based on Clinical Symptoms and Clinical History among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. International Journal of Research and Reports in Gynaecology. 2022;5(3):98-105.
31. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of some haematological parameters in malaria infected pregnant women in Imo state Nigeria. Int. J. Curr. Res. Biol. Med. 2018;3(9):1-4.DOI: 10.22192/ijcrbm.2018.03.09.001
32. Obeagu EI. Erythrocyte enumeration and serum erythropoietin in chronic kidney disease patients: A study in Federal Medical Centre, Umuahia, Nigeria. International Journal of Advanced Research in Biological Sciences. 2016;3(7):163-70.

33. Ifeanyi OE. A review on erythropoietin. Int J Adv Res Biol Sci. 2015;2(4):35-47.
34. Obeagu EI. Maximizing longevity: erythropoietin's impact on sickle cell anemia survival rates. Annals of Medicine and Surgery. 2024:10-97.
35. Ifeanyi OE, Uzoma OG. A review on erythropietin in pregnancy. J. Gynecol. Womens Health. 2018;8(3):1-4.
36. Obeagu EI, Okoroiwu IL, Obeagu GU. Relationship between Thrombopoietin and Interleukin 3: A Review. Int J Curr Res Chem Pharm. Sci. 2022;9(1):7-13.
37. Obeagu EI, Obeagu GU, Amilo GI. Haematological changes in patients of chronic kidney disease in Umuahia, Abia State, Nigeria. Curr Trends Biomed Eng Biosci. 2018; 11:34-7.
38. Obeagu EI, Okoroiwu IL, Azuonwu O. An update on hypoxic regulation of iron homeostasis and bone marrow environment. Int. J. Curr. Res. Med. Sci. 2018;4(10):42-8.
39. Obeagu EI. Blood Transfusion: A Powerful Process of Saving Anaemic Patients. EC Emergency Medicine and Critical Care. 2020;4(7):33-40.
40. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
41. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. APPLIED SCIENCES (NIJBAS). 2023;3(3).
42. Obeagu EI. Maximizing longevity: erythropoietin's impact on sickle cell anemia survival rates. Annals of Medicine and Surgery. 2024:10-97.
43. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
44. Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among youths: A review of Africa perspective. Madonna University journal of Medicine and Health Sciences. 2023;3(1):13-18. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93.
45. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.
46. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.
47. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
48. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004

49. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. Int. J. Curr. Res. Med. Sci. 2023;9(2): 1-5.DOI: 10.22192/ijcrms.2023.09.02.001
50. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
51. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
52. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
53. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
54. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.
55. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
56. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
57. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
58. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
59. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-

SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.

60. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;130. links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf.
61. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
62. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
63. Onyenweaku FC, Amah HC, Obeagu EI, Nwandikor UU, Onwuasoanya UF. Prevalence of asymptomatic bacteriuria and its antibiotic susceptibility pattern in pregnant women attending private ante natal clinics in Umuahia Metropolitan. Int J Curr Res Biol Med. 2017;2(2):13-23.DOI: 10.22192/ijcrbm.2017.02.02.003
64. Okoroiwu IL, Chinedu-Madu JU, Obeagu EI, Vincent CC, Ochiabuto OM, Ibekwe AM, Amaechi CO, Agu CC, Anoh NV, Amadi NM. Evaluation of Iron Status, Haemoglobin and Protein Levels of Pregnant Women in Owerri Metropolis. Journal of Pharmaceutical Research International. 2021 Apr 29;33(27A):36-43.
65. Obeagu EI, Njar VE, Obeagu GU. Infertility: Prevalence and Consequences. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(7):43-50.
66. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM. Evaluation of levels of some inflammatory cytokines in preeclamptic women in owerri. Journal of Pharmaceutical Research International. 2021 Aug 25;33(42A):53-65.
67. Obeagu EI, Faduma MH, Uzoma G. Ectopic Pregnancy: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):40-4.DOI: 10.22192/ijcrcps.2023.10.04.004
68. Obeagu EI, Gamade SM, Obeagu GU. The roles of Neutrophils in pregnancy. Int. J. Curr. Res. Med. Sci. 2023;9(5):31-5.DOI: 10.22192/ijcrms.2023.09.05.005
69. Eze R, Obeagu EI, Nwakulite A, Okoroiwu IL, Vincent CC, Okafor CJ, Chukwurah EF, Chijioke UO, Amaechi CO. Evaluation of Copper Status and Some Red Cell Parameters of Pregnant Women in Enugu State, South Eastern Nigeria. Journal of Pharmaceutical Research International. 2021 May 29;33(30A):67-71.
70. Obeagu EI, Obeagu GU. Molar Pregnancy: Update of prevalence and risk factors. Int. J. Curr. Res. Med. Sci. 2023;9(7):25-8.DOI: 10.22192/ijcrms.2023.09.07.005
71. Obeagu EI, Bunu UO. Factors that influence unmet need for family planning. International Journal of Current Research in Biology and Medicine. 2023;8(1):23-7.
72. Ibebuike JE, Ojie CA, Nwokike GI, Obeagu EI, Nwosu DC, Nwanjo HU, Agu GC, Ezenwuba CO, Nwagu SA, Akujuobi AU. Barriers to utilization of maternal health services

in southern senatorial district of Cross Rivers state, Nigeria. International Journal of Advanced Multidisciplinary Research. 2017;4(8):1-9.DOI: 10.22192/ijamr.2017.04.08.001

73. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
74. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
75. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
76. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
77. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
78. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
79. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.
80. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf
81. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
82. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci.

2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf

83. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
84. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian Journal of Dental and Health Sciences. 2023;3(2):7-14. http://ajdhs.com/index.php/journal/article/view/39.
85. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** 10.32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
86. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
87. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.
88. Sargin D, Friedrichs H, El-Kordi A, Ehrenreich H. Erythropoietin as neuroprotective and neuroregenerative treatment strategy: comprehensive overview of 12 years of preclinical and clinical research. Best practice & research Clinical anaesthesiology. 2010;24(4):573-594.